Cargando…

Models for predicting venous thromboembolism in ambulatory patients with lung cancer: a systematic review protocol

INTRODUCTION: Venous thromboembolism (VTE) is a common complication in patients with cancer and has a determining role in the disease prognosis. The risk is significantly increased with certain types of cancer, such as lung cancer. Partly due to difficulties in managing haemorrhage in outpatient set...

Descripción completa

Detalles Bibliográficos
Autores principales: Yan, Ann-Rong, Samarawickrema, Indira, Naunton, Mark, Peterson, Gregory M, Yip, Desmond, Mortazavi, Reza
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8638451/
https://www.ncbi.nlm.nih.gov/pubmed/34853112
http://dx.doi.org/10.1136/bmjopen-2021-055322
_version_ 1784608948095025152
author Yan, Ann-Rong
Samarawickrema, Indira
Naunton, Mark
Peterson, Gregory M
Yip, Desmond
Mortazavi, Reza
author_facet Yan, Ann-Rong
Samarawickrema, Indira
Naunton, Mark
Peterson, Gregory M
Yip, Desmond
Mortazavi, Reza
author_sort Yan, Ann-Rong
collection PubMed
description INTRODUCTION: Venous thromboembolism (VTE) is a common complication in patients with cancer and has a determining role in the disease prognosis. The risk is significantly increased with certain types of cancer, such as lung cancer. Partly due to difficulties in managing haemorrhage in outpatient settings, anticoagulant prophylaxis is only recommended for ambulatory patients at high risk of VTE. This requires a precise VTE risk assessment in individual patients. Although VTE risk assessment models have been developed and updated in recent years, there are conflicting reports on the effectiveness of such risk prediction models in patient management. The aim of this systematic review is to gain a better understanding of the available VTE risk assessment tools for ambulatory patients with lung cancer and compare their predictive performance. METHODS AND ANALYSIS: A systematic review will be conducted using MEDLINE, Cochrane Library, CINAHL, Scopus and Web of Science databases from inception to 30 September 2021, to identify all reports published in English describing VTE risk prediction models which have included adult ambulatory patients with primary lung cancer for model development and/or validation. Two independent reviewers will conduct article screening, study selection, data extraction and quality assessment of the primary studies. Any disagreements will be referred to a third researcher to resolve. The included studies will be assessed for risk of bias and applicability. The Checklist for Critical Appraisal and Data Extraction for Systematic Reviews of Prediction Modelling Studies will be used for data extraction and appraisal. Data from similar studies will be used for meta-analysis to determine the incidence of VTE and the performance of the risk models. ETHICS AND DISSEMINATION: Ethics approval is not required. We will disseminate the results in a peer-reviewed journal. PROSPERO REGISTRATION NUMBER: CRD42021245907.
format Online
Article
Text
id pubmed-8638451
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-86384512021-12-15 Models for predicting venous thromboembolism in ambulatory patients with lung cancer: a systematic review protocol Yan, Ann-Rong Samarawickrema, Indira Naunton, Mark Peterson, Gregory M Yip, Desmond Mortazavi, Reza BMJ Open Oncology INTRODUCTION: Venous thromboembolism (VTE) is a common complication in patients with cancer and has a determining role in the disease prognosis. The risk is significantly increased with certain types of cancer, such as lung cancer. Partly due to difficulties in managing haemorrhage in outpatient settings, anticoagulant prophylaxis is only recommended for ambulatory patients at high risk of VTE. This requires a precise VTE risk assessment in individual patients. Although VTE risk assessment models have been developed and updated in recent years, there are conflicting reports on the effectiveness of such risk prediction models in patient management. The aim of this systematic review is to gain a better understanding of the available VTE risk assessment tools for ambulatory patients with lung cancer and compare their predictive performance. METHODS AND ANALYSIS: A systematic review will be conducted using MEDLINE, Cochrane Library, CINAHL, Scopus and Web of Science databases from inception to 30 September 2021, to identify all reports published in English describing VTE risk prediction models which have included adult ambulatory patients with primary lung cancer for model development and/or validation. Two independent reviewers will conduct article screening, study selection, data extraction and quality assessment of the primary studies. Any disagreements will be referred to a third researcher to resolve. The included studies will be assessed for risk of bias and applicability. The Checklist for Critical Appraisal and Data Extraction for Systematic Reviews of Prediction Modelling Studies will be used for data extraction and appraisal. Data from similar studies will be used for meta-analysis to determine the incidence of VTE and the performance of the risk models. ETHICS AND DISSEMINATION: Ethics approval is not required. We will disseminate the results in a peer-reviewed journal. PROSPERO REGISTRATION NUMBER: CRD42021245907. BMJ Publishing Group 2021-12-01 /pmc/articles/PMC8638451/ /pubmed/34853112 http://dx.doi.org/10.1136/bmjopen-2021-055322 Text en © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Oncology
Yan, Ann-Rong
Samarawickrema, Indira
Naunton, Mark
Peterson, Gregory M
Yip, Desmond
Mortazavi, Reza
Models for predicting venous thromboembolism in ambulatory patients with lung cancer: a systematic review protocol
title Models for predicting venous thromboembolism in ambulatory patients with lung cancer: a systematic review protocol
title_full Models for predicting venous thromboembolism in ambulatory patients with lung cancer: a systematic review protocol
title_fullStr Models for predicting venous thromboembolism in ambulatory patients with lung cancer: a systematic review protocol
title_full_unstemmed Models for predicting venous thromboembolism in ambulatory patients with lung cancer: a systematic review protocol
title_short Models for predicting venous thromboembolism in ambulatory patients with lung cancer: a systematic review protocol
title_sort models for predicting venous thromboembolism in ambulatory patients with lung cancer: a systematic review protocol
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8638451/
https://www.ncbi.nlm.nih.gov/pubmed/34853112
http://dx.doi.org/10.1136/bmjopen-2021-055322
work_keys_str_mv AT yanannrong modelsforpredictingvenousthromboembolisminambulatorypatientswithlungcancerasystematicreviewprotocol
AT samarawickremaindira modelsforpredictingvenousthromboembolisminambulatorypatientswithlungcancerasystematicreviewprotocol
AT nauntonmark modelsforpredictingvenousthromboembolisminambulatorypatientswithlungcancerasystematicreviewprotocol
AT petersongregorym modelsforpredictingvenousthromboembolisminambulatorypatientswithlungcancerasystematicreviewprotocol
AT yipdesmond modelsforpredictingvenousthromboembolisminambulatorypatientswithlungcancerasystematicreviewprotocol
AT mortazavireza modelsforpredictingvenousthromboembolisminambulatorypatientswithlungcancerasystematicreviewprotocol